83_FR_26178 83 FR 26070 - Government-Owned Inventions; Availability for Licensing

83 FR 26070 - Government-Owned Inventions; Availability for Licensing

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 83, Issue 108 (June 5, 2018)

Page Range26070-26071
FR Document2018-12017

The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S.

Federal Register, Volume 83 Issue 108 (Tuesday, June 5, 2018) 
[Federal Register Volume 83, Number 108 (Tuesday, June 5, 2018)]
[Notices]
[Pages 26070-26071]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2018-12017]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing in the U.S.

FOR FURTHER INFORMATION CONTACT: Licensing information and copies of 
the patent applications listed below may be obtained by emailing the 
indicated licensing contact at the National Heart, Lung, and Blood, 
Office of Technology Transfer and Development, Office of Technology 
Transfer, 31 Center Drive, Room 4A29, MSC 2479, Bethesda, MD 20892-
2479; telephone: 301-402-5579. A signed Confidential Disclosure 
Agreement may be required to receive copies of the patent applications.

SUPPLEMENTARY INFORMATION: This notice is in accordance with 35 U.S.C. 
209 and 37 CFR part 404 to achieve commercialization of results of 
federally-funded research and development. Foreign patent applications 
are filed on selected inventions to extend market coverage for 
companies and may also be available for licensing. A description of the 
technology follows.

Octopod (8-Pointed Star) Iron Oxide Nanoparticles Enhance MRI T2 
Contrast

    Description of Technology: The octopod-shaped iron oxide 
nanoparticles of this technology significantly enhance contrast in MRI 
imaging compared to spherical superparamagnetic iron oxide nanoparticle 
T2 contrast agents. These octopod iron oxide nanoparticles show a 
transverse relaxivity that is over five times greater than comparable 
spherical agents. Because the unique octopod shape creates a greater 
effective radius than spherical agents, but maintains similar 
magnetization properties, the relaxation rate is improved. The improved 
relaxation rate greatly enhances the contrast of images. These octopod 
agents appear to be bio-compatible and may be suitable for intravenous 
delivery. The synthesis of these agents is also easily reproducible and 
scaled. The superior contrast greatly improves diagnostic 
sensitivities, compared to current FDA approved spherical contrast 
agents. These octopod-shaped iron oxide nanoparticle T2 contrast agents 
may have a number of medical imaging uses, such as tumor detection, 
atherosclerosis imaging and delivery of therapeutic treatments.
    Potential Commercial Applications: Medical imaging, such as tumor 
detection, atherosclerosis imaging and delivery of therapeutic 
treatments.
    Competitive Advantages:

--Enhanced T2 contrast
--Reproducible and scalable synthesis
--Improved imaging and diagnostic capability

    Development Stage: In vivo data available (animal).
    Inventors: Xiaoyuan Chen (NIBIB), Jinhao Gao (Xiamen University, 
China), Zhenghuan Zhao (Xiamen University, China).
    Publication: Zhao Z, et al. Octapod iron oxide nanoparticles as 
high-performance T2 contrast agents for magnetic resonance imaging. Nat 
Commun. 2013;4:2266. [PMID 23903002]
    Intellectual Property: HHS Reference No. E-314-2013/0--PCT 
Application No. PCT/CN2013/076645 filed June 3, 2013. Chinese Patent 
Application 201380077163.3 filed December 3, 2015.

[[Page 26071]]

European Patent 3003394 issued May 23, 2018 (validated in Switzerland, 
Germany, France, the United Kingdom, and Ireland), U.S. Patent 
9,974,868 issued May 22, 2018.
    Licensing Contact: Michael A. Shmilovich; 301-435-5019; 
shmilovm@mail.nih.gov.
    Collaborative Research Opportunity: The National Institute of 
Biomedical Imaging and Bioengineering is seeking statements of 
capability or interest from parties interested in collaborative 
research to further develop, evaluate or commercialize this technology. 
For collaboration opportunities, please contact Cecilia Pazman, Ph.D. 
at pazmance@mail.nih.gov.

    Dated: May 21, 2018.
Michael A. Shmilovich,
Senior Licensing and Patenting Manager, National Heart, Lung, and Blood 
Institute, Office of Technology Transfer and Development.
[FR Doc. 2018-12017 Filed 6-4-18; 8:45 am]
 BILLING CODE 4140-01-P

26070 Federal Register / Vol. 83, No. 108 / Tuesday, June 5, 2018 / Notices this notice. The statement should include the Boulevard, Rockville, MD 20852 (Telephone commercialization of results of name, address, telephone number and when Conference Call). federally-funded research and applicable, the business or professional Contact Person: Ernest W. Lyons, Ph.D., development. Foreign patent affiliation of the interested person. Scientific Review Officer, Scientific Review Branch, NINDS/NIH/DHHS, Neuroscience applications are filed on selected In the interest of security, NIH has instituted stringent procedures for entrance Center, 6001 Executive Blvd, Suite 3208, inventions to extend market coverage onto the NCI-Shady Grove campus. All MSC 9529, Bethesda, MD 20892–9529, (301) for companies and may also be available visitors will be asked to show one form of 496–4056, lyonse@ninds.nih.gov. for licensing. A description of the identification (for example, a government- Name of Committee: National Institute of technology follows. issued photo ID, driver’s license, or passport) Neurological Disorders and Stroke Special and to state the purpose of their visit. Emphasis Panel; Research Education Octopod (8-Pointed Star) Iron Oxide Information is also available on the Programs for Residents and Fellows. Nanoparticles Enhance MRI T2 Institute’s/Center’s home page: NCAB: http:// Date: June 29, 2018. Contrast deainfo.nci.nih.gov/advisory/ncab/ncab.htm, Time: 11:00 a.m. to 3:00 p.m. Description of Technology: The BSA: http://deainfo.nci.nih.gov/advisory/ Agenda: To review and evaluate grant applications. octopod-shaped iron oxide bsa/bsa.htm, where an agenda and any additional information for the meeting will Place: National Institutes of Health, nanoparticles of this technology be posted when available. Neuroscience Center, 6001 Executive significantly enhance contrast in MRI (Catalogue of Federal Domestic Assistance Boulevard, Rockville, MD 20852 (Telephone imaging compared to spherical Program Nos. 93.392, Cancer Construction; Conference Call). superparamagnetic iron oxide 93.393, Cancer Cause and Prevention Contact Person: Ernest W. Lyons, Ph.D., nanoparticle T2 contrast agents. These Research; 93.394, Cancer Detection and Scientific Review Officer, Scientific Review octopod iron oxide nanoparticles show Diagnosis Research; 93.395, Cancer Branch, NINDS/NIH/DHHS, Neuroscience a transverse relaxivity that is over five Treatment Research; 93.396, Cancer Biology Center, 6001 Executive Blvd, Suite 3208, MSC 9529, Bethesda, MD 20892–9529, (301) times greater than comparable spherical Research; 93.397, Cancer Centers Support; agents. Because the unique octopod 93.398, Cancer Research Manpower; 93.399, 496–4056, lyonse@ninds.nih.gov. Cancer Control, National Institutes of Health, (Catalogue of Federal Domestic Assistance shape creates a greater effective radius HHS) Program Nos. 93.853, Clinical Research than spherical agents, but maintains Related to Neurological Disorders; 93.854, similar magnetization properties, the Dated: May 30, 2018. relaxation rate is improved. The Biological Basis Research in the Melanie J. Pantoja, Neurosciences, National Institutes of Health, improved relaxation rate greatly Program Analyst, Office of Federal Advisory HHS) enhances the contrast of images. These Committee Policy. octopod agents appear to be bio- Dated: May 30, 2018. [FR Doc. 2018–11958 Filed 6–4–18; 8:45 am] compatible and may be suitable for Sylvia L. Neal, BILLING CODE 4140–01–P Program Analyst, Office of Federal Advisory intravenous delivery. The synthesis of Committee Policy. these agents is also easily reproducible [FR Doc. 2018–11963 Filed 6–4–18; 8:45 am] and scaled. The superior contrast greatly DEPARTMENT OF HEALTH AND improves diagnostic sensitivities, BILLING CODE 4140–01–P HUMAN SERVICES compared to current FDA approved spherical contrast agents. These National Institutes of Health octopod-shaped iron oxide nanoparticle DEPARTMENT OF HEALTH AND National Institute of Neurological HUMAN SERVICES T2 contrast agents may have a number Disorders and Stroke; Notice of Closed of medical imaging uses, such as tumor Meetings National Institutes of Health detection, atherosclerosis imaging and delivery of therapeutic treatments. Pursuant to section 10(d) of the Government-Owned Inventions; Potential Commercial Applications: Federal Advisory Committee Act, as Availability for Licensing Medical imaging, such as tumor amended, notice is hereby given of the AGENCY: National Institutes of Health, detection, atherosclerosis imaging and following meetings. HHS. delivery of therapeutic treatments. The meetings will be closed to the Competitive Advantages: ACTION: Notice. public in accordance with the —Enhanced T2 contrast provisions set forth in sections SUMMARY: The inventions listed below —Reproducible and scalable synthesis 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., are owned by an agency of the U.S. —Improved imaging and diagnostic as amended. The grant applications and Government and are available for capability the discussions could disclose licensing in the U.S. Development Stage: In vivo data confidential trade secrets or commercial FOR FURTHER INFORMATION CONTACT: available (animal). property such as patentable material, Licensing information and copies of the Inventors: Xiaoyuan Chen (NIBIB), and personal information concerning patent applications listed below may be Jinhao Gao (Xiamen University, China), individuals associated with the grant obtained by emailing the indicated Zhenghuan Zhao (Xiamen University, applications, the disclosure of which licensing contact at the National Heart, China). would constitute a clearly unwarranted Lung, and Blood, Office of Technology Publication: Zhao Z, et al. Octapod invasion of personal privacy. Transfer and Development, Office of iron oxide nanoparticles as high- Name of Committee: National Institute of Technology Transfer, 31 Center Drive, performance T2 contrast agents for Neurological Disorders and Stroke Special Room 4A29, MSC 2479, Bethesda, MD magnetic resonance imaging. Nat amozie on DSK3GDR082PROD with NOTICES1 Emphasis Panel; Summer Research 20892–2479; telephone: 301–402–5579. Commun. 2013;4:2266. [PMID Education Experience Programs. A signed Confidential Disclosure 23903002] Date: June 19, 2018. Agreement may be required to receive Time: 1:00 p.m. to 4:00 p.m. Intellectual Property: HHS Reference Agenda: To review and evaluate grant copies of the patent applications. No. E–314–2013/0—PCT Application applications. SUPPLEMENTARY INFORMATION: This No. PCT/CN2013/076645 filed June 3, Place: National Institutes of Health, notice is in accordance with 35 U.S.C. 2013. Chinese Patent Application Neuroscience Center, 6001 Executive 209 and 37 CFR part 404 to achieve 201380077163.3 filed December 3, 2015. VerDate Sep<11>2014 20:19 Jun 04, 2018 Jkt 241001 PO 00000 Frm 00076 Fmt 4703 Sfmt 4703 E:\FR\FM\05JNN1.SGM 05JNN1

Federal Register / Vol. 83, No. 108 / Tuesday, June 5, 2018 / Notices 26071 European Patent 3003394 issued May Name of Committee: Center for Scientific would constitute a clearly unwarranted 23, 2018 (validated in Switzerland, Review Special Emphasis Panel; RFA–RM– invasion of personal privacy. Germany, France, the United Kingdom, 18–016: Innovative Technologies to Deliver Genome Editing Machinery to Disease- Name of Committee: National Institute of and Ireland), U.S. Patent 9,974,868 General Medical Sciences Special Emphasis relevant Cells and Tissues. issued May 22, 2018. Date: June 29, 2018. Panel; Review of Centers of Biomedical Licensing Contact: Michael A. Time: 8:00 a.m. to 6:00 p.m. Research Excellence (COBRE) (P20) Shmilovich; 301–435–5019; shmilovm@ Agenda: To review and evaluate grant Applications. mail.nih.gov. Date: July 16, 2018. applications. Time: 8:00 a.m. to 5:00 p.m. Collaborative Research Opportunity: Place: Hyatt Regency Bethesda, One Agenda: To review and evaluate grant The National Institute of Biomedical Bethesda Metro Center, 7400 Wisconsin applications. Imaging and Bioengineering is seeking Avenue, Bethesda, MD 20814. Place: Cambria Hotel & Suite Rockville, 1 statements of capability or interest from Contact Person: Luis Dettin, Ph.D., Helen Heneghan Way, Rockville, MD 20850. Scientific Review Officer, Center for Contact Person: Manas Chattopadhyay, parties interested in collaborative Scientific Review, National Institutes of Ph.D., Scientific Review Officer, Office of research to further develop, evaluate or Health, 6701 Rockledge Drive, Room 2208, commercialize this technology. For Scientific Review, National Institute of Bethesda, MD 20892, 301 451 1327, dettinle@ General Medical Sciences, National Institutes collaboration opportunities, please csr.nih.gov. of Health, Building 45, Room 3An12N, 45 contact Cecilia Pazman, Ph.D. at Name of Committee: Center for Scientific Center Drive, Bethesda, md 20892, 301–827– pazmance@mail.nih.gov. Review Special Emphasis Panel; Member 5320, manasc@mail.nih.gov. Dated: May 21, 2018. Conflict: Cancer Immunopathology and (Catalogue of Federal Domestic Assistance Immunotherapy. Program Nos. 93.375, Minority Biomedical Michael A. Shmilovich, Date: July 3, 2018. Research Support; 93.821, Cell Biology and Senior Licensing and Patenting Manager, Time: 1:00 p.m. to 5:00 p.m. National Heart, Lung, and Blood Institute, Biophysics Research; 93.859, Pharmacology, Agenda: To review and evaluate grant Physiology, and Biological Chemistry Office of Technology Transfer and applications. Research; 93.862, Genetics and Development. Place: National Institutes of Health, 6701 Developmental Biology Research; 93.88, [FR Doc. 2018–12017 Filed 6–4–18; 8:45 am] Rockledge Drive, Bethesda, MD 20892 Minority Access to Research Careers; 93.96, BILLING CODE 4140–01–P (Telephone Conference Call). Special Minority Initiatives; 93.859, Contact Person: Lawrence Ka-Yun Ng, Biomedical Research and Research Training, Ph.D., Scientific Review Officer, Center for National Institutes of Health, HHS) DEPARTMENT OF HEALTH AND Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6152, Dated: May 30, 2018. HUMAN SERVICES Melanie J. Pantoja, MSC 7804, Bethesda, MD 20892, 301–435– National Institutes of Health 1719, ngkl@csr.nih.gov. Program Analyst, Office of Federal Advisory (Catalogue of Federal Domestic Assistance Committee Policy. Center for Scientific Review: Notice of Program Nos. 93.306, Comparative Medicine; [FR Doc. 2018–11960 Filed 6–4–18; 8:45 am] Closed Meetings 93.333, Clinical Research, 93.306, 93.333, BILLING CODE 4140–01–P 93.337, 93.393–93.396, 93.837–93.844, Pursuant to section 10(d) of the 93.846–93.878, 93.892, 93.893, National Federal Advisory Committee Act, as Institutes of Health, HHS) DEPARTMENT OF HEALTH AND amended, notice is hereby given of the Dated: May 30, 2018. HUMAN SERVICES following meetings. David D. Clary, The meetings will be closed to the Program Analyst, Office of Federal Advisory National Institutes of Health public in accordance with the Committee Policy. provisions set forth in sections National Institute of General Medical [FR Doc. 2018–11957 Filed 6–4–18; 8:45 am] 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., Sciences; Notice of Closed Meeting BILLING CODE 4140–01–P as amended. The grant applications and Pursuant to section 10(d) of the the discussions could disclose Federal Advisory Committee Act, as confidential trade secrets or commercial DEPARTMENT OF HEALTH AND amended, notice is hereby given of the property such as patentable material, HUMAN SERVICES following meeting. and personal information concerning The meeting will be closed to the individuals associated with the grant National Institutes of Health public in accordance with the applications, the disclosure of which provisions set forth in sections would constitute a clearly unwarranted National Institute of General Medical 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., invasion of personal privacy. Sciences; Notice of Closed Meeting as amended. The grant applications and Name of Committee: Center for Scientific Pursuant to section 10(d) of the the discussions could disclose Review Special Emphasis Panel; PAR–18– Federal Advisory Committee Act, as confidential trade secrets or commercial 669: Limited Competition: Specific Pathogen property such as patentable material, Free Macaque Colonies. amended, notice is hereby given of the following meeting. and personal information concerning Date: June 28, 2018. individuals associated with the grant Time: 10:00 a.m. to 1:00 p.m. The meeting will be closed to the applications, the disclosure of which Agenda: To review and evaluate grant public in accordance with the applications. would constitute a clearly unwarranted provisions set forth in sections Place: National Institutes of Health, 6701 invasion of personal privacy. 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., amozie on DSK3GDR082PROD with NOTICES1 Rockledge Drive, Bethesda, MD 20892 as amended. The grant applications and Name of Committee: National Institute of (Telephone Conference Call). the discussions could disclose General Medical Sciences Special Emphasis Contact Person: Barna Dey, Ph.D., Panel; Review of NIH Pathway to Scientific Review Officer, Center for confidential trade secrets or commercial Independence Award K99/R00 Applications. Scientific Review, National Institutes of property such as patentable material, Date: July 19, 2018. Health, 6701 Rockledge Drive, Room 3184, and personal information concerning Time: 8:00 a.m. to 5:00 p.m. Bethesda, MD 20892, 301–451–2796, bdey@ individuals associated with the grant Agenda: To review and evaluate grant mail.nih.gov. applications, the disclosure of which applications. VerDate Sep<11>2014 20:19 Jun 04, 2018 Jkt 241001 PO 00000 Frm 00077 Fmt 4703 Sfmt 4703 E:\FR\FM\05JNN1.SGM 05JNN1


Document Created: 2018-11-02 11:46:08
Document Modified: 2018-11-02 11:46:08
CategoryRegulatory Information
CollectionFederal Register
sudoc ClassAE 2.7:
GS 4.107:
AE 2.106:
PublisherOffice of the Federal Register, National Archives and Records Administration
SectionNotices
ActionNotice.
ContactLicensing information and copies of the patent applications listed below may be obtained by emailing the indicated licensing contact at the National Heart, Lung, and Blood, Office of Technology Transfer and Development, Office of Technology Transfer, 31 Center Drive, Room 4A29, MSC 2479, Bethesda, MD 20892- 2479; telephone: 301-402-5579. A signed Confidential Disclosure Agreement may be required to receive copies of the patent applications.
FR Citation83 FR 26070 
2024 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR